MAZE (Maze Therapeutics) Long-Term Debt: $38.83 Mil (As of Mar. 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $30.56
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Long-Term Debt?

Maze Therapeutics MAZE -5.82% 14 Long-Term Debt is $38.83 Mil as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Maze Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $38.83 Mil.

Maze Therapeutics's quarterly Long-Term Debt stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($38.83 Mil).

Maze Therapeutics's annual Long-Term Debt declined from Dec. 2023 ($20.08 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Maze Therapeutics  (NAS:MAZE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Maze Therapeutics Long-Term Debt Related Terms

Maze Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Long-Term Debt Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 20.08 0.00 0.00

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 38.83
MAZE
14GF Score
Maze Therapeutics Inc MAZE
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $38.83 Mil mean?
Maze Therapeutics (MAZE) has a Long-Term Debt of $38.83 Mil as of Mar. 2026.
Is Maze Therapeutics' Long-Term Debt too high?
Maze Therapeutics' current Long-Term Debt is $38.83 Mil. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Long-Term Debt compare to AVBP and DMRA?
Maze Therapeutics' Long-Term Debt of $38.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Maze Therapeutics's current Long-Term Debt is $38.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Long-Term Debt of $38.83 Mil. The current Long-Term Debt is $38.83 Mil. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Long-Term Debt is $38.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.56
Price